Medlab Clinical Ltd
ASX:MDC
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
Medlab Clinical Ltd
ASX:MDC
|
15.1m AUD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.8B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.4B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Medlab Clinical Ltd
Glance View
Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2015-07-14. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use. The firm also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia, United States, and the United Kingdom.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Medlab Clinical Ltd is 100%, which is above its 3-year median of 91.7%.
Over the last 3 years, Medlab Clinical Ltd’s Gross Margin has increased from 93.2% to 100%. During this period, it reached a low of 73.4% on Jun 30, 2022 and a high of 100% on Jul 30, 2024.
